CompletedEUCTR 2010-021143-41
An Open-Label, Multicenter, Rollover, Long-term Study of Aripiprazole Intramuscular Depot in Patients with Schizophrenia
This historical record does not confirm current site availability.
Historical research recordMultiple countries
Understand this study
What did researchers investigate?
This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.
Who was this study for?
This study was for people with schizophrenia. Other eligibility criteria applied.
- Listed locations
- Bulgaria · Estonia and 4 more locations
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateNot clearly listed
- Recruitment status
- Completed
- Enrollment listed in the registry
- 800
- Sponsor
- Otsuka Pharmaceutical Development and Commercialization, Inc.
- Sponsor type
- Pharmaceutical company
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- Bulgaria, Estonia, Finland, ...
- Age range
- Not clearly listed
- Official registry ID
- EUCTR 2010-021143-41
- Official title
Show the full official title
An Open-Label, Multicenter, Rollover, Long-term Study of Aripiprazole Intramuscular Depot in Patients with Schizophrenia
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Bulgaria · Estonia · Finland
3 more locations
- Hungary
- Slovakia
- Spain
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Otsuka Pharmaceutical Development and Commercialization, Inc., a pharmaceutical company.
Who was this study for?
This study was for people with schizophrenia. Other eligibility criteria applied.
Want to explore more studies?
Explore studiesRelated studies
A 12-WEEK, MULTICENTER, OPEN-LABEL EXTENSION STUDY IN SUBJECTS WITH SCHIZOPHRENIA
A 12-Week, Open-Label Extension Study of Lurasidone (SM-13496) in Subjects with Schizophrenia